TSPY2

Across TCGA pan-cancer cohorts, TSPY2 RNA is linked to patient survival in 11 of 34 cancer types, making it the most broadly survival-associated TSPY2 data layer.

The strongest signal is observed in kidney chromophobe (KICH), where higher TSPY2 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated TSPY2 expression acts as an unfavorable survival marker, although some lineages such as LGG and TGCT show a favorable association.

KICH, UCEC, and BLCA are the cancer types where TSPY2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KICH	DFS	Tertile	All	0.081	0.904	<.001	90	view →
UCEC	DFS	Tertile	II,III,IV	0.206	0.825	<.001	54	view →
BLCA	OS	Tertile	All	0.090	0.688	<.001	54	view →
LIHC	DFS	Tertile	All	0.392	0.593	<.001	51	view →
LUAD	OS	Tertile	II,III,IV	0.314	0.571	.006	42	view →
DLBC	OS	Tertile	All	0.053	0.936	<.001	36	view →
ESCA	OS	Tertile	All	0.198	0.872	.003	36	view →
LGG	OS	Median	All	0.949	0.827	<.001	19	view →
PRAD	OS	Tertile	All	0.588	0.916	<.001	12	view →
STAD	DFS	Tertile	II,III,IV	0.276	0.535	.007	9	view →
TGCT	DFS	Median	All	0.788	0.585	.029	4	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

TSPY2–KICH (DFS)

Open the KICH breakdown →